why choose us

First received: July 13, 2023

Clinical Trial: High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Myocardial Fibrosis

Study Type: INTERVENTIONAL


Official Title: High Relaxivity Contrast Agent for Cardiac MR in the Myocardial Scar Assessment

Brief Summary: Elucirem (Gadopiclenol) is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity indicated for use in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging.The product was approved in 2022 by FDA to be used to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine and associated tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).However, given its at least twofold higher…

Read more